Christina Poh, MD

Christina Poh, MD

Physician, Fred Hutchinson Cancer Center
Assistant Professor, Division of Hematology and Oncology
University of Washington School of Medicine
Seattle, Washington

Related Videos

What current ongoing studies are evaluating the role of duvelisib as part of a first-line combinatorial regimen that would be used along with CHOP upon confirmation of PTCL-TFH? Video

What current ongoing studies are evaluating the role of duvelisib as part of a first-line combinatorial regimen that would be used along with CHOP upon confirmation of PTCL-TFH?

Based on your real world experience with duvelisib in PTCL-TFH, what role do you see for this agent? Video

Based on your real world experience with duvelisib in PTCL-TFH, what role do you see for this agent?

Trials such as PRIMO have reported on multiple dosing regimens of duvelisib. How do you dose duvelisib in the R/R setting and when used for bridging in patients awaiting allograft stem cell transplantation? Video

Trials such as PRIMO have reported on multiple dosing regimens of duvelisib. How do you dose duvelisib in the R/R setting and when used for bridging in patients awaiting allograft stem cell transplantation?

Can you discuss what the current post-CHOP therapy landscape looks like for persons with PTCL-TFH, in particular for patients who have relapsed, failed, and/or are resistant to CHOP? Video

Can you discuss what the current post-CHOP therapy landscape looks like for persons with PTCL-TFH, in particular for patients who have relapsed, failed, and/or are resistant to CHOP?

At what point with PTCL-TFH do you introduce duvelisib treatment? Do you use it in the first-line setting or do you currently reserve it for R/R patients and as a bridge for allograft stem cell transplantion? Video

At what point with PTCL-TFH do you introduce duvelisib treatment? Do you use it in the first-line setting or do you currently reserve it for R/R patients and as a bridge for allograft stem cell transplantion?

Can you discuss your experience with duvelisib in persons with the PTCL-TFH subtype and what range of response rates you have observed, as well as your deployment of duvelisib as bridge therapy for patients awaiting allograft stem cell transplant? Video

Can you discuss your experience with duvelisib in persons with the PTCL-TFH subtype and what range of response rates you have observed, as well as your deployment of duvelisib as bridge therapy for patients awaiting allograft stem cell transplant?

What do you see as the near future role of duvelisib in this patient subgroup, even before the results of the TERZO trial are reported? Video

What do you see as the near future role of duvelisib in this patient subgroup, even before the results of the TERZO trial are reported?

What’s your rationale for duvelisib dosing in: (1) bridging to allogeneic transplant, (2) achieving CR in R/R PTCL-TFH, and (3) palliative care? Video

What’s your rationale for duvelisib dosing in: (1) bridging to allogeneic transplant, (2) achieving CR in R/R PTCL-TFH, and (3) palliative care?

How do you use the NCCN guidelines, and specifically, their specific recommendations endorsing duvelisib as both monotherapy and in combination with romidepsin? Video

How do you use the NCCN guidelines, and specifically, their specific recommendations endorsing duvelisib as both monotherapy and in combination with romidepsin?